ID: MRFR/Pharma/2776-HCR | February 2021 | Region: Global | 90 pages
Tularemia or rabbit fever or deer fly fever is a rare infectious disease caused by the bacterium Francisella tularensis, which affects skin, eyes, lymph nodes and lungs. Tularemia is transmitted from animals such as rodents, rabbits, and hares to human. It can also affect sheep, birds, dogs, cats, etc. The routes of acquiring infection are direct exposure to the bacteria, airborne infections, insect bites, and bite of an infected animal. Tularemia is highly contagious and had been used as a biological weapon by many countries such as United States of America and Soviet Union. Ulceroglandular tularemia is the most common form of Tularemia. Tularemia symptoms include swollen and painful lymph glands, fever, chills, headache, fatigue, eye swelling, pain and light sensitivity, diarrhea, pneumonia etc. If it left untreated, it will cause serious complications such as enlarged spleen, enlarged liver, infection around the brain and spinal cord, irritation around the heart (pericarditis), bone infection etc. and may lead to the death.
Factors favouring the spread of Tularemia infection are tick bites, exposure to sick or dead animals, especially, wild game. Travel to certain regions such as Arkansas, Missouri and Oklahoma can also cause Tularemia infection because of the concentration of ticks in those areas. Tick bite is the leading cause for an occurrence of large number of cases.Laboratory workers working with tularemia are at risk of airborne infection due to greater chances of exposure to the pathogen. Tularemia infection can also be airborne during gardening, construction or other activities, which may lead to pneumonic tularemia. Tularemia is also contracted by eating undercooked meat of an infected animal or drinking contaminated water. According to Centers for Disease Control and Prevention, overall mortality of Tularemia is less than 2% but ranges up to 24% depending on the strain.
The Tularemia market is expected to reach US$ 200 million by 2023, and the tularemia market is projected to grow at a CAGR of ~ 3.2 % during the forecast period 2017-2023.
Sources: U.S. Department of Health and Human Services National Institutes of Health, Centers for Disease Control and Prevention, Mayo Clinic, MRFR Analysis
The Tularemia market has been segmented on the basis of types, diagnosis, drugs, and end users.
Based on types, the tularemia market has been segmented as the ulceroglandular tularemia, glandular tularemia, oculoglandular tularemia, oropharyngeal tularemia, pneumonic tularemia, and others.
Based on the diagnosis, the tularemia market has been segmented as microscopy, immunochemistry, and others.
Based on the drugs, the tularemia market has been segmented as streptomycin, gentamicin, doxycycline, ciprofloxacin and others.
Based on the end users, the tularemia market has been segmented as hospitals and clinics, academic and research centers, and others.
The Americas accounts for the significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new technology and drugs in the US drives the Tularemia market. However the presence and concentration of Tularemia in the US regions, for instance, Arkansas, Missouri, Dakota, Oklahoma, etc. are the leading cause for the dominance of US in the Tularemia market. Europe is the second largest market in the globe due to a high disposable income and rising awareness about the disease.
Asia Pacific region is expected to grow rapidly and China and India are likely to lead the tularemia market due to unmet needs during the forecast period.
Gulf nations such as Saudi Arabia and the UAE drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development. However Africa is also a region of high endemic and untreated cases of Tularemia.
Key Players in the Tularemia Market
Some of key players profiled in the report are Nicholas Piramal, Alkem, Glaxo Smithkline, Bayer AG, Ranbaxy Laboratories, Cipla Inc., Zydus Cadila, Dr. Reddy's Lab, Glenmark Pharmaceuticals, Lupin Limited, pfizer Inc. and others.
The report for Tularemia market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the tularemia market and industry performance. The report gives a clear picture of the current tularemia market scenario which includes past and estimated future tularemia market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
|CAGR||3.2 % (2017-2023)|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Types, Diagnosis, Drugs, and End Users|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Nicholas Piramal, Alkem, Glaxo Smithkline, Bayer AG, Ranbaxy Laboratories, Cipla Inc., Zydus Cadila, Dr. Reddy's Lab, Glenmark Pharmaceuticals, Lupin Limited, pfizer Inc. and others|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
Tularemia market is projected to grow at a 3.2% CAGR between 2017-2023.
The Americas is expected to dominate the tularemia market.
The tularemia market is predicted to touch 200 million by 2023.
Some common symptoms of tularemia include eye swelling, fever, pneumonia, fatigue, and others.
Different types of tularemia include pneumonic tularemia, oropharyngeal tularemia, oculoglandular tularemia, glandular tularemia, and ulceroglandular tularemia.
1.2 Scope of Study
1.2.1 Research Objective
1.2.2 Assumptions & Limitations
1.3 Market Structure
2. Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3. Market dynamics
3.4 Macroeconomic Indicators
4. Market factor analysis
4.1 Porters Five Forces Model
4.2 Bargaining Power of Suppliers
4.3 Bargaining Power of Buyers
4.4 Threat of New Entrants
4.5 Threat of Substitutes
4.6 Intensity of Rivalry
5. Global Tularemia Market, by Type
5.1 Ulceroglandular Tularemia
5.2 Glandular Tularemia
5.3 Oculoglandular Tularemia
5.4 Oropharyngeal Tularemia
5.5 Pneumonic TularemiA
6. Global Tularemia Market, by Diagnosis
7. Global Tularemia Market, by Drugs
8. Global U reteral Obstruction Market, by End Users
8.1 Hospitals And Clinics
8.2 Academic and Research Centres
9. Global Tularemia Market, by Region
9.1 North America
9.3 Asia Pacific
9.4 Middle East & Africa
10. Competitive landscape
10.1 Major Strategies Adopted by Market Players
10.1.1 Strategic Partnership
10.1.2 Merger & Acquisition
11. Company profile
11.1 Nicholas Piramal
11.1.2 Product Overview
11.1.4 Key Developments
11.2 Glaxo Smithkline
11.2.2 Product Overview
11.2.4 Key Developments
11.3 Bayer AG
11.3.2 Product Overview
11.3.4 Key Development
11.4 Ranbaxy Laboratories
11.4.2 Product Overview
11.4.4 Key Developments
11.5 Glenmark Pharmaceuticals
11.5.2 Product Overview
11.5.4 Key Developments
11.7 Dr. Reddy's Lab,
11.7.2 Product Overview
11.7.4 Key Developments
11.7 Pfizer Inc.
11.7.2 Product Overview
11.7.4 Key Developments
11.8 Cipla Inc.
11.8.2 Product Overview
11.8.4 Key Developments
11.9 Lupin Limited
11.9.2 Product Overview
11.9.4 Key Developments
11.10 Zydus Cadila
11.11.2 Product Overview
11.11.4 Key Developments
12.1 Key Findings
12.1.1 From CEO’s Viewpoint
12.1.2 Unmet Needs of The Market
12.2 Key Companies to Watch
12.3 Prediction of Tularemia Industry